Key facts
- CrannMed’s last known valuation is $32.7M (Oct 2025).
- It has raised $24.6M; the latest was Later Stage VC ($11.8M) in Feb 2026.
- Notable investors include Enterprise Ireland, European Innovation Council, European Commission, EIT Health, Merit Medical Systems.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for CrannMed
- ·The full record, as it builds
Funding rounds
No funding rounds for CrannMed are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About CrannMed
Operator of a medical company intended to serve the growing particle embolization market. The company aims at developing resorbable embolic particles and a custom delivery catheter for the treatment of knee osteoarthritis, enabling healthcare professionals to improve patient outcomes in a very minimally invasive way.
- Sector
- Healthcare
- HQ
- Galway, Ireland
- Founded
- 2018
- Employees
- 15
- Website
- crannmed.com/
- Ownership
- Privately Held (backing)
CrannMed doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in CrannMed shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on CrannMed in its N-PORT filings yet. We sweep new filings monthly.